Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Definium Therapeutics, Inc. (DFTX) had Return on Equity of -27.65% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-77.10M |
|
-- |
|
-- |
|
$59.22M |
|
$-59.22M |
|
$-17.88M |
|
$-77.10M |
|
$-77.10M |
|
$-77.10M |
|
$-77.10M |
|
$-77.10M |
|
$-77.10M |
|
$-59.22M |
|
$-58.63M |
|
108.79M |
|
108.79M |
|
$-0.71 |
|
$-0.71 |
|
| Balance Sheet Financials | |
$380.56M |
|
-- |
|
$20.73M |
|
$401.29M |
|
$81.11M |
|
$40.77M |
|
$41.33M |
|
$122.44M |
|
$278.85M |
|
$258.93M |
|
$278.85M |
|
104.05M |
|
| Cash Flow Statement Financials | |
$-42.63M |
|
$42.00M |
|
$5.31M |
|
$257.84M |
|
$262.52M |
|
$4.68M |
|
$7.13M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.69 |
|
-- |
|
-- |
|
0.13 |
|
0.15 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-42.63M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-27.65% |
-29.78% |
|
-19.21% |
|
-24.12% |
|
$2.68 |
|
$-0.39 |
|
$-0.39 |
|